SignalPoint Asset Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% during the third quarter, Holdings Channel reports. The firm owned 11,967 shares of the company’s stock after buying an additional 291 shares during the period. SignalPoint Asset Management LLC’s holdings in Johnson & Johnson were worth $1,414,000 as of its most recent filing with the SEC.
Several other hedge funds also recently added to or reduced their stakes in JNJ. Emerald Acquisition Ltd. bought a new stake in Johnson & Johnson during the second quarter worth $805,455,000. Vanguard Group Inc. raised its stake in Johnson & Johnson by 2.2% in the second quarter. Vanguard Group Inc. now owns 184,512,652 shares of the company’s stock worth $22,381,384,000 after buying an additional 3,924,090 shares during the period. BlackRock Fund Advisors raised its stake in Johnson & Johnson by 5.5% in the second quarter. BlackRock Fund Advisors now owns 42,089,045 shares of the company’s stock worth $5,105,401,000 after buying an additional 2,192,319 shares during the period. Capital World Investors raised its stake in Johnson & Johnson by 10.3% in the second quarter. Capital World Investors now owns 22,025,323 shares of the company’s stock worth $2,671,672,000 after buying an additional 2,050,323 shares during the period. Finally, Capital International Investors bought a new stake in Johnson & Johnson during the second quarter worth $227,704,000. 65.28% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson (NYSE:JNJ) opened at 113.38 on Friday. The firm has a 50-day moving average price of $114.94 and a 200 day moving average price of $117.77. Johnson & Johnson has a 12 month low of $99.78 and a 12 month high of $126.07. The stock has a market capitalization of $308.45 billion, a PE ratio of 19.12 and a beta of 0.72.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, January 24th. The company reported $1.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.56 by $0.02. The firm earned $18.10 billion during the quarter, compared to analyst estimates of $18.28 billion. Johnson & Johnson had a return on equity of 25.61% and a net margin of 22.78%. The business’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.44 EPS. Equities analysts anticipate that Johnson & Johnson will post $7.03 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 14th. Stockholders of record on Tuesday, February 28th will be given a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 2.82%. The ex-dividend date is Friday, February 24th. Johnson & Johnson’s payout ratio is 54.42%.
JNJ has been the subject of a number of analyst reports. Vetr lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $117.54 price objective for the company. in a research note on Monday, November 7th. RBC Capital Markets set a $133.00 target price on Johnson & Johnson and gave the company a “buy” rating in a report on Wednesday, November 9th. Zacks Investment Research downgraded Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Tuesday, January 3rd. Barclays PLC downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $130.00 to $125.00 in a report on Tuesday, November 29th. They noted that the move was a valuation call. Finally, Bank of America Corporation restated a “hold” rating and set a $126.00 target price on shares of Johnson & Johnson in a report on Monday, November 28th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and eight have issued a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus price target of $122.52.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).